Today: 11 June 2026
Salesforce stock slips after-hours as Spring ’26 AI agent push lands — what to watch next
10 January 2026
1 min read

Salesforce stock slips after-hours as Spring ’26 AI agent push lands — what to watch next

New York, January 9, 2026, 19:31 EST — After-hours

  • Salesforce shares down about 0.2% late Friday
  • Company detailed Spring ’26 release; rollout starts Feb. 23
  • Next tests: U.S. CPI on Jan. 13, then Salesforce earnings expected Feb. 25

Salesforce (CRM) shares slipped about 0.2% in after-hours trading on Friday after the company laid out its Spring ’26 product release, a set of updates aimed at pushing “AI agents” deeper into sales and service work. Salesforce said the rollout starts Feb. 23 and adds tools such as an AI-led “Sales Workspace” and “Proactive Service.” Salesforce

The timing matters because big software names are being asked a simple question early in 2026: can they turn all the AI talk into checks. Investors have been quick to punish anything that looks like a slow payback cycle.

Salesforce is betting on “AI agents” — software that can take actions in business systems, not just answer prompts — to keep customers buying add-ons and renewing at higher prices. A new release is nice; the market usually waits for evidence in billings and guidance.

On Thursday, Salesforce also published an “AI Fluency Playbook” pitched at helping companies train workers to collaborate with those agents. “When we get AI fluency right, AI moves from a technology innovation into a workforce advantage,” said Nathalie Scardino, Salesforce’s president and chief people officer, while Pearson CHRO Ali Bebo called the moment “all about learning agility.” Salesforce said its own use of Agentforce in Slack saved employees more than 500,000 hours in a year. Salesforce

Friday’s move came against a choppy tape for enterprise software. Oracle rose nearly 5% while ServiceNow fell about 3%, with the S&P 500 ending higher, MarketWatch data showed.

Salesforce’s last set of results, released in early December, lifted its full-year fiscal 2026 revenue forecast to $41.45 billion to $41.55 billion and pointed to nearly $1.4 billion in annual recurring revenue from Agentforce and Data 360. “We are raising fiscal year 2026 revenue guidance,” CEO Marc Benioff said at the time. ARR is a measure of subscription revenue expected to repeat each year. Salesforce

Macro still sets the tone for how much investors will pay for long-dated growth. U.S. consumer price index data for December are due on Jan. 13, and the Federal Reserve’s next policy meeting runs Jan. 27-28.

For Salesforce specifically, the next scheduled catalyst is its earnings report. The company is slated to report on Feb. 25, according to Yahoo Finance’s earnings calendar.

At around $260 a share, Salesforce carries a market value of roughly $244 billion and sits about 29% below its 52-week high and around 17% above its low, MarketWatch data show.

But the rollouts come with familiar risks: big customers may test AI tools without expanding paid usage, rivals can pressure pricing, and any renewed jump in yields can weigh on the whole group. Traders now look to Feb. 25 for the next hard read on demand and guidance — and that tends to decide the next leg for CRM.

Stock Market Today

  • PIMCO ETFs PLC Declares Key Dividend Dates for June 2026
    June 11, 2026, 10:57 AM EDT. PIMCO ETFs PLC announced important dividend-related dates: a record date on June 17, 2026, followed by a pay date on June 18, 2026. The ex-dividend date, which is the cutoff to buy the ETF to receive the dividend, is set for June 11, 2026. These dates are critical for investors tracking income and dividend payouts from PIMCO ETFs, signaling when shares must be held to qualify for dividend payments.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Kohl’s stock slides 5% as tariff ruling delay hits retailers; KSS traders eye Jan. 14
Previous Story

Kohl’s stock slides 5% as tariff ruling delay hits retailers; KSS traders eye Jan. 14

Lululemon stock drops nearly 4% as tariff ruling stays unresolved — what to watch next
Next Story

Lululemon stock drops nearly 4% as tariff ruling stays unresolved — what to watch next

Go toTop